source
- Eli Lilly teams with Hong Kong's Metis TechBio in up to $1.1 billion AI nanoparticle partnershipEli Lilly has entered a partnership with Hong Kong‑based Metis TechBio to access an artificial‑intelligence driven platform for designing lipid nanoparticles that can improve drug delivery. The co…
- TCGX uses SPAC to take migraine biotech TriGemX public, securing $246M for phase-3 trialTCGX, a life‑sciences investment firm, announced it will merge its SPAC with TriGemX Bio, a biotech focused on migraine treatments. TriGemX, formerly known as Kallyope, is developing a TRPM8 chann…